Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota
about
Molecular biology of lung cancer: clinical implicationsCancer of the Pancreas: Molecular Pathways and Current Advancement in TreatmentPredictive biomarkers in precision medicine and drug development against lung cancerSynthetic lethality in lung cancer and translation to clinical therapiesProtein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung AdenocarcinomaIdentification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cellsTargeting p53 for Novel Anticancer Therapy.Oxidative stress in NSC-741909-induced apoptosis of cancer cellsDistinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell linesKLF4 inhibition of lung cancer cell invasion by suppression of SPARC expression.Ferroptosis: an iron-dependent form of nonapoptotic cell deathAntitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibitionDevelopment of small-molecule probes that selectively kill cells induced to express mutant RASSynthetic lethality: general principles, utility and detection using genetic screens in human cellsProdrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agentsAntagonistic effect of flavonoids on NSC-741909-mediated antitumor activity via scavenging of reactive oxygen species.Development of synthetic lethality anticancer therapeutics.Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.Analogues and derivatives of oncrasin-1, a novel inhibitor of the C-terminal domain of RNA polymerase II and their antitumor activities.Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stressExpression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380Anti-lung cancer potential of pure esteric-glycoside condurangogenin A against nonsmall-cell lung cancer cells in vitro via p21/p53 mediated cell cycle modulation and DNA damage-induced apoptosis.Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cellsSTAT3 mediates resistance to MEK inhibitor through microRNA miR-17.Killing of Kras-mutant colon cancer cells via Rac-independent actin remodeling by the βGBP cytokine, a physiological PI3K inhibitor therapeutically effective in vivoRAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasisInterruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1).Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells.Targeted regulation of PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapyRegulation of polarized morphogenesis by protein kinase C iota in oncogenic epithelial spheroids.Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).Genetic Interactions of STAT3 and Anticancer Drug Development.Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.Simultaneous determination and validation of oncrasin-266 and its metabolites by HPLC-MS/MS: Application to a pharmacokinetic studyDefeat mutant KRAS with synthetic lethality.Protein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesisAnti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities.
P2860
Q24610335-711484A8-58C1-47D2-89FB-22FD0E3BCD0AQ26740619-8F10C338-B9D0-442F-8F7D-4D0EE6AE386CQ26824536-04C1DDC0-C74D-46DB-9045-DBAF9EEA453BQ28072904-ACEF9F22-B4D3-490F-8FA5-EC4F5A20BD05Q28115044-B2DA0612-FF57-487A-AC1B-2A70EEFA7FE7Q28284818-37E5CCED-35B8-46CA-ADAE-BB8EE6B0D420Q33655329-82488245-55DC-4ED3-B94E-B48DD1316B03Q33863911-C21D92BF-EBBE-4DBD-81C4-83BF0880FDD6Q33913913-AE1C03B5-2790-484D-A6D5-83CBA8349FD0Q33987695-0DB961BB-C74D-43A3-A8FC-9925F7C2993AQ34032093-ED140255-1CF8-47E7-8652-2983B4F6E0E1Q34103117-26E65221-8B09-4870-9F4B-D2D3519ED806Q34148375-C7301E15-C2DB-4C75-828F-F5448438989AQ34151015-A945AF70-6C20-44C8-997A-67FD0A145C7FQ34231935-88410ADA-D025-4C86-A3C5-5CB276DA29A9Q34240999-6425D002-C7EE-45F4-89B1-73878A2A21D2Q34259118-B7CC65CD-5CD2-4BBD-8C62-A4193B9B9EACQ34380368-247593EA-5A01-4C57-8892-0171716354DAQ34659415-C5EC762B-8452-4803-AD4E-DB82018C0F73Q34857289-6C29322A-30E8-49F7-BA9F-DD42EC18C9A1Q35008361-C059B88E-EC72-4B04-991C-64D838A08C0FQ35238466-C0BAB5F0-0D81-42E1-85FE-806C2BD49C48Q35709966-286EDE9B-837F-4257-9D01-5B048450DCC3Q36081620-EA7D48B1-2923-492A-B9A7-FDD3C097149DQ36083385-90118FA9-8920-45D0-95E5-67F1204E257CQ36227159-05B37F1C-3E6B-4F53-BE7A-C6A59EFC96D0Q36398735-E824902F-9B86-4308-B388-3C2231DD4E0DQ36861954-2D391A1D-9BBA-4BD1-9767-205723F1FB28Q37121568-5152C28B-8371-4953-8ED5-D90FF4D1B76EQ37285084-83E71D68-7A4C-4539-A042-23681DBE888AQ37512204-DBD8F284-26EF-4E4B-85D4-D41283C10741Q37537542-5A352C82-9A7D-47E2-A0D7-B7C5497E08E1Q38046230-8FB429CB-E196-4F8B-9F6C-A95B945F3E0CQ38198930-CD82C5C9-1E2A-46CD-922E-3E042D9F1D55Q38238743-FED5D8AA-6EFA-4A50-B564-41B5D3FECA32Q38736995-5D8E44FA-03E4-403B-829C-26CDB22A5DDBQ38829776-A73D54CA-57F3-4989-BB0F-DA11B951100AQ38837319-BA70F894-6520-4B75-B9E2-9A4BFD4C9849Q39736038-D6DF1BEC-401C-4D7F-B126-E4C2F0C1FB01Q46237281-FDFEA16E-1D7B-4AC9-903F-E737DEF88C15
P2860
Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Identification of a small mole ...... -ras and protein kinase C iota
@ast
Identification of a small mole ...... -ras and protein kinase C iota
@en
Identification of a small mole ...... -ras and protein kinase C iota
@nl
type
label
Identification of a small mole ...... -ras and protein kinase C iota
@ast
Identification of a small mole ...... -ras and protein kinase C iota
@en
Identification of a small mole ...... -ras and protein kinase C iota
@nl
prefLabel
Identification of a small mole ...... -ras and protein kinase C iota
@ast
Identification of a small mole ...... -ras and protein kinase C iota
@en
Identification of a small mole ...... -ras and protein kinase C iota
@nl
P2093
P2860
P1433
P1476
Identification of a small mole ...... -ras and protein kinase C iota
@en
P2093
Bingliang Fang
Jinsong Liu
Shuhong Wu
P2860
P304
P356
10.1158/0008-5472.CAN-08-1449
P407
P577
2008-09-01T00:00:00Z